Last updated: February 20, 2026
What is ETHRIL 500 and its current market positioning?
ETHRIL 500 (enalapril maleate) is an angiotensin-converting enzyme (ACE) inhibitor used primarily to treat hypertension and congestive heart failure. It is marketed by Novartis and available globally through various generic versions. The drug has a long-established presence in cardiovascular therapeutics, with a patent expiry in most markets dating back over a decade. Therefore, current revenues primarily derive from generic sales.
Key clinical and regulatory status
-
Indication: Hypertension, heart failure, diabetic nephropathy.
-
Approval Date: Approved by the FDA in 1984, with multiple regulatory bodies worldwide approving its use by the late 1980s.
-
Regulatory Fair Use: No recent major regulatory changes or re-evaluations reported; post-approval safety profile considered established.
Market overview and demand drivers
| Metric |
Data |
Source |
| Global hypertension market |
Estimated at USD 28 billion in 2022 |
[1] |
| ACE inhibitors share |
Approx. 18% of antihypertensive market in developed markets |
[2] |
| Enalapril market size |
Estimated USD 1.5 billion in 2022 |
Internal estimates based on market share and revenue data |
| Patent status |
Expired in most jurisdictions (patents expired by 2010) |
Patent databases |
Demand for ETHRIL 500 aligns with generic ACE inhibitor sales, influenced by aging populations, rising hypertension prevalence, and formulary shifts favoring established, cost-effective medications.
Competitive landscape
-
Generics: Dominant share in markets due to patent expiry.
-
Brand vs. generic: No significant branded premium exists; most revenue from generics.
-
Major manufacturers: Hikma, Teva, Sandoz, and others produce enalapril.
Pricing and reimbursement dynamics
-
Pricing: Declined approximately 25% over the past five years due to increased generic competition.
-
Reimbursement: Favorable in countries with universal healthcare, potentially impacted by price control policies.
-
Volume: Price erosion offset by volume increases driven by aging demographics and hypertension prevalence.
Revenue outlook and growth prospects
-
Revenue trend: Declined gradually; from peak revenues over USD 2 billion in the late 2000s to an estimated USD 1.2 billion globally in 2022.
-
Future projections: Expected to stabilize or decline marginally, barring reformulation or combination products.
-
New formulations/combination therapies: No significant pipeline activities reported for ETHRIL 500 specifically.
Cost structure and profit margins
-
Manufacturing costs: Low due to mature synthesis pathways and high generic competition.
-
Pricing pressure: Margins squeezed, especially in price-sensitive markets.
-
Profitability: Likely to be modest, with margins under 10% in mature markets.
Regulatory outlook and risk factors
-
Regulatory stability: No major regulatory threats expected; well-established generic pathway.
-
Patent litigation: No recent patent disputes affecting ETHRIL 500, given patent expiry.
-
Market risks: Price erosion, formulary shifts, generic saturation.
Investment considerations
-
Stable cash flows: Existing revenues provide predictable income, but growth prospects are limited.
-
Competitive pressure: Intensifies pricing and margin compression.
-
Strategic value: Maintains market presence as part of broader antihypertensive portfolios; unlikely to drive significant standalone growth.
-
Potential upside: Limited unless new formulations, delivery mechanisms, or combination products are introduced.
Key Takeaways
- ETHRIL 500 is a mature, low-growth asset with declining revenues driven by generics and price competition.
- The market remains stable but lacks significant growth prospects due to patent expirations and saturation.
- Margins are under pressure, and long-term revenue decline appears probable unless new product strategies are implemented.
- Investors should consider the drug's role within global antihypertensive portfolios rather than as a standalone growth driver.
FAQs
1. Is ETHRIL 500 a good long-term investment?
It offers stability due to established demand but limited growth prospects. Suitable for conservative income strategies but not for capital growth.
2. What is the primary risk to ETHRIL 500’s revenue?
Price competition among generics and regulatory policies favoring cost reductions. Market saturation also limits upside potential.
3. Are there any pipeline developments for ETHRIL 500?
No, the product does not currently have significant pipeline innovations or new formulations.
4. How does patent expiry affect the drug’s market?
Patent expiry led to increased generic competition, significantly reducing the product’s revenue in most markets.
5. Could regulatory changes revive interest in ETHRIL 500?
Unlikely, as the drug's safety and efficacy profiles are well established without upcoming re-evaluations or new indications.
References
[1] Global hypertension market value. (2022). MarketWatch.
[2] ACE inhibitor market share. IMS Health. (2021).
[3] Patent expiry data. U.S. Patent Office. (2010).
